Anti-Thrombomodulin antibody [B-A35] (ab27393)

Overview

  • Product nameAnti-Thrombomodulin antibody [B-A35]
    See all Thrombomodulin primary antibodies
  • Description
    Mouse monoclonal [B-A35] to Thrombomodulin
  • SpecificityRecognises the soluble thrombomodulin antigen
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    TF1 cell line

  • Positive control
    • Monocytes

Properties

Applications

Our Abpromise guarantee covers the use of ab27393 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use at an assay dependent concentration. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

Target

  • FunctionThrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated.
  • Tissue specificityEndothelial cells are unique in synthesizing thrombomodulin.
  • Involvement in diseaseDefects in THBD are the cause of thrombophilia due to thrombomodulin defect (THR-THBD) [MIM:188040]. A hemostatic disorder characterized by a tendency to thrombosis.
    Defects in THBD are a cause of susceptibility to hemolytic uremic syndrome atypical type 6 (AHUS6) [MIM:612926]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similaritiesContains 1 C-type lectin domain.
    Contains 6 EGF-like domains.
  • Post-translational
    modifications
    N-glycosylated.
    The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AHUS 6 antibody
    • AHUS6 antibody
    • BDCA 3 antibody
    • BDCA3 antibody
    • CD 141 antibody
    • CD141 antibody
    • CD141 antigen antibody
    • Fetomodulin antibody
    • Thbd antibody
    • THPH12 antibody
    • THRM antibody
    • Thrombomodulin antibody
    • TM antibody
    • TRBM_HUMAN antibody
    see all

Anti-Thrombomodulin antibody [B-A35] images

  • A typical staining pattern with the ab27393 of monocytes

References for Anti-Thrombomodulin antibody [B-A35] (ab27393)

ab27393 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab27393.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"